Krishnaswamy Yeleswaram - 24 Aug 2026 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
26 Aug 2026, 16:00:03 UTC
Prior SEC filing
20 Aug 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Troy Ignelzi, Attorney-in-Fact

Key filing fact

Krishnaswamy Yeleswaram filed Form 4 for Rapport Therapeutics, Inc. (RAPP) on 26 Aug 2026.

Key facts

  • This page summarizes Krishnaswamy Yeleswaram's Form 4 filing for Rapport Therapeutics, Inc. (RAPP).
  • 3 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 26 Aug 2026, 16:00.

Change

  • Previous filing in this sequence was filed on 20 Aug 2026.
  • Current net transaction value: -$2,531,582.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002022156 Primary reporting owner

Yeleswaram Krishnaswamy

Relationship
Chief Development Officer
Address
RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Signature date
26 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RAPP transaction

Common Stock

Sale

Transaction value
$657,978
Shares
-13,160
Change %
-5.3%
Price
$50.00
Shares after
232,862
Date
24 Aug 2026
Ownership
Direct
Footnotes
F1, F2
RAPP transaction

Common Stock

Sale

Transaction value
$1,046,421
Shares
-20,799
Change %
-8.9%
Price
$50.31
Shares after
212,063
Date
25 Aug 2026
Ownership
Direct
Footnotes
F1, F3
RAPP transaction

Common Stock

Sale

Transaction value
$827,184
Shares
-16,201
Change %
-7.6%
Price
$51.06
Shares after
195,862
Date
25 Aug 2026
Ownership
Direct
Footnotes
F1, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .